Upload Records Snowball Search Search OpenAlex
About the database ScholarIQanswers from OpenAlex & ORCID
Melinda Gooderham
ResearcherPublications, citations & collaboration network
Melinda Gooderham is a researcher indexed in ScholarIQ from OpenAlex & ORCID. ScholarIQ records 579 works, 16,115 citations, an h-index of 60 and an i10-index of 199.
579
Works
16,115
Citations
60
h-index
199
i10-index
How has Melinda Gooderham's publication output changed over time?
ScholarIQpublication output · 2015–2023
Output grew0% over the shown period — from 1 works in 2015 to 1 in 2023.
1
2
2
1
1
2
1
1
1
201520162017201820192020202120222023
What are the most-cited papers on Melinda Gooderham?
ScholarIQmost cited works
Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial
Andrew Blauvelt, Marjolein de Bruin‐Weller, Melinda Gooderham, Jennifer Clay Cather, Jamie Weisman, David M. Pariser, Eric L. Simpson, Kim Papp, Hyuck-Ki Hong, Diana Rubel, Peter Foley, Errol P. Prens, C.E.M. Griffiths, Takafumi Etoh, Pedro Herranz, Ramón M. Pujol, Jacek C. Szepietowski, Karel Ettler, Lajos Kemény, Xiaoping Zhu, Bolanle Akinlade, Thomas Hultsch, Vera Mastey, Abhijit Gadkari, Laurent Eckert, Nikhil Amin, Neil M.H. Graham, Gianluca Pirozzi, Neil Stahl, George D. Yancopoulos, Brad Shumel
The Lancet. 20171,258 CitationsOPEN ACCESS
Risankizumab versus Ustekinumab for Moderate-to-Severe Plaque Psoriasis
Kim Papp, Andrew Blauvelt, Michael Bukhalo, Melinda Gooderham, James G. Krueger, J.‐P. Lacour, Alan Menter, Sandra Philipp, Howard Sofen, Stephen K. Tyring, B Berner, Sudha Visvanathan, Chandrasena Pamulapati, Nathan Bennett, Mary Flack, Paul Scholl, Steven J. Padula
New England Journal of Medicine. 2017514 CitationsOPEN ACCESS
Efficacy and Safety of Dupilumab in Adolescents With Uncontrolled Moderate to Severe Atopic Dermatitis
Eric L. Simpson, Amy S. Paller, Elaine C. Siegfried, Mark Boguniewicz, Lawrence Sher, Melinda Gooderham, Lisa A. Beck, Emma Guttman‐Yassky, David M. Pariser, Andrew Blauvelt, Jamie Weisman, Benjamin Lockshin, Thomas Hultsch, Qin Zhang, Mohamed Kamal, John D. Davis, Bolanle Akinlade, Heribert Staudinger, Jennifer D. Hamilton, Neil M.H. Graham, Gianluca Pirozzi, Abhijit Gadkari, Laurent Eckert, Neil Stahl, George D. Yancopoulos, Marcella Ruddy, Ashish Bansal
JAMA Dermatology. 2019514 CitationsOPEN ACCESS
Efficacy and safety of apremilast, an oral phosphodiesterase 4 inhibitor, in patients with moderate‐to‐severe plaque psoriasis over 52 weeks: a phase III, randomized controlled trial (ESTEEM 2)
C. Paul, Jennifer Clay Cather, Melinda Gooderham, Yves Poulin, Ulrich Mrowietz, C. Ferrandiz, J. Crowley, ChiaChi Hu, R.M. Stevens, Kara N. Shah, R. M. Day, Giampiero Girolomoni, A.B. Gottlieb
British Journal of Dermatology. 2015480 CitationsOPEN ACCESS
Phase 2 Trial of Selective Tyrosine Kinase 2 Inhibition in Psoriasis
Kim Papp, Kenneth B. Gordon, Diamant Thaçi, Akimichi Morita, Melinda Gooderham, Peter Foley, Ihab Girgis, Sudeep Kundu, Subhashis Banerjee
New England Journal of Medicine. 2018420 CitationsOPEN ACCESS
Related on ScholarIQ
Queen's University
Institution
Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial
Paper
Risankizumab versus Ustekinumab for Moderate-to-Severe Plaque Psoriasis
Paper
Efficacy and Safety of Dupilumab in Adolescents With Uncontrolled Moderate to Severe Atopic Dermatitis
Paper
Efficacy and safety of apremilast, an oral phosphodiesterase 4 inhibitor, in patients with moderate‐to‐severe plaque psoriasis over 52 weeks: a phase III, randomized controlled trial (ESTEEM 2)
Paper
Phase 2 Trial of Selective Tyrosine Kinase 2 Inhibition in Psoriasis
Paper